Table 2.
Human Cancers | Numbers (Clinical Cases/Controls) | Clinical Significance | Reference |
---|---|---|---|
Glioma | 87 glioma tissues and 81 normal brain tissues | ↑pathological grade | 9,20,24 |
Nasopharyngeal carcinoma (NPC) | 64 NPC tissues and adjacent normal breast tissues | ↑tumor stage, ↓overall survival | 18 |
Breast cancer (BRCA) | 30 BRCA tissues and adjacent normal breast tissues | ↑tumor stage, ↑tumor size, ↓overall survival | 25–28 |
Hepatocellular carcinoma (HCC) | 79 HCC specimens and non-tumor tissues | ↑tumor size, ↑HBV infection, ↑histologic grade, ↑TNM stage, ↑PVTT, ↓overall survival | 30,31 |
Gastric cancer (GC) | 13 pairs of GC tissues and non-tumor tissues | ↑cisplatin resistance | 32,33 |
158 GC tissues and non-tumor tissues | ↓CEA level, ↓TNM grade, ↓tumor embolus formation | 34 | |
Colorectal cancer (CRC) | 69 couples of CRC and adjacent tissues | ↑tumor stage | 16,21 |
Renal cell carcinoma (RCC) | 52 RCC tissues and adjacent normal kidney tissues | ↑TNM stage, ↑tumor size, ↑lymphatic invasion, ↑distant metastasis | 35,36 |
Bladder cancer (BC) | 67 BC tissues and matched non-cancerous tissues | ↑tumor range, ↑metastasis, ↑lymph nodes invasion, ↑pathological stage, ↓overall survival | 23 |
Endometrial cancer (EC) | 86 EC tissues and non-cancer tissues | ↓clinical stage, ↑overall survival, ↑disease-free survival | 12 |
Acute myeloid leukemia (AML) | 101 AML patients and 53 healthy volunteers | ↑FAB classification, ↑unfavorable cytogenetics, ↓overall survival | 13,37,38 |
Chronic myeloid leukemia (CML) | 40 CML patients and 20 healthy volunteers | imatinib resistance | 14,22 |
Melanoma (MM) | 50 MM tissues and matched normal tissues | ↑pathological stag, ↑metastasis | 15,39 |
Osteosarcoma (OS) | 32 pairs of OS tissues and adjacent normal tissues | ↑tumor size, ↑tumor grade, ↑metastasis, ↑Enneking stage, ↓overall survival | 17,40 |
Abbreviations: HBV, hepatitis B virus; TNM, tumor-node-metastasis; PVTT, portal vein tumor thrombus; CEA, carcinoembryonic antigen.